JP Morgan Chase’s Avanos Medical AVNS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Sell |
-1,099,770
| Closed | -$27.4M | – | 8255 |
|
|
2026
Q2 | $27.4M | Buy |
1,099,770
+848,608
| +338% | +$19.9M | ﹤0.01% | 1962 |
|
|
2026
Q1 | $3.45M | Sell |
251,162
-22,556
| -8% | -$304K | ﹤0.01% | 3678 |
|
|
2025
Q4 | $3.07M | Sell |
273,718
-304,171
| -53% | -$3.48M | ﹤0.01% | 3754 |
|
|
2025
Q3 | $6.68M | Buy |
577,889
+311,317
| +117% | +$3.65M | ﹤0.01% | 3120 |
|
|
2025
Q2 | $3.26M | Sell |
266,572
-84,033
| -24% | -$1.06M | ﹤0.01% | 3548 |
|
|
2025
Q1 | $5.02M | Buy |
350,605
+148,971
| +74% | +$2.33M | ﹤0.01% | 3169 |
|
|
2024
Q4 | $3.21M | Buy |
201,634
+132,063
| +190% | +$2.61M | ﹤0.01% | 3781 |
|
|
2024
Q3 | $1.67M | Buy |
69,571
+4,472
| +7% | +$102K | ﹤0.01% | 4151 |
|
|
2024
Q2 | $1.3M | Sell |
65,099
-62,019
| -49% | -$1.21M | ﹤0.01% | 4115 |
|
|
2024
Q1 | $2.53M | Sell |
127,118
-76,110
| -37% | -$1.47M | ﹤0.01% | 3673 |
|
|
2023
Q4 | $4.56M | Hold |
203,228
| – | – | ﹤0.01% | 3190 |
|
|
2023
Q3 | $5.01M | Buy |
247,539
+131,222
| +113% | +$2.97M | ﹤0.01% | 2863 |
|
|
2023
Q2 | $2.97M | Buy |
116,317
+13,497
| +13% | +$355K | ﹤0.01% | 3271 |
|
|
2023
Q1 | $3.06M | Buy |
102,820
+9,481
| +10% | +$275K | ﹤0.01% | 3219 |
|
|
2022
Q4 | $2.53M | Sell |
93,339
-724
| -0.8% | -$17.7K | ﹤0.01% | 3403 |
|
|
2022
Q3 | $2.05M | Sell |
94,063
-161,086
| -63% | -$4.21M | ﹤0.01% | 3454 |
|
|
2022
Q2 | $6.98M | Buy |
255,149
+175,806
| +222% | +$5.05M | ﹤0.01% | 2487 |
|
|
2022
Q1 | $2.66M | Buy |
79,343
+29,216
| +58% | +$941K | ﹤0.01% | 3543 |
|
|
2021
Q4 | $1.74M | Buy |
50,127
+2,470
| +5% | +$79.9K | ﹤0.01% | 3968 |
|
|
2021
Q3 | $1.49M | Sell |
47,657
-2,409
| -5% | -$81.7K | ﹤0.01% | 4015 |
|
|
2021
Q2 | $1.82M | Sell |
50,066
-169,065
| -77% | -$6.99M | ﹤0.01% | 3868 |
|
|
2021
Q1 | $9.6M | Buy |
219,131
+111,415
| +103% | +$5.23M | ﹤0.01% | 2407 |
|
|
2020
Q4 | $4.94M | Sell |
107,716
-10,972
| -9% | -$457K | ﹤0.01% | 2835 |
|
|
2020
Q3 | $3.92M | Buy |
118,688
+63,186
| +114% | +$2.02M | ﹤0.01% | 2768 |
|
|
2020
Q2 | $1.63M | Buy |
55,502
+1,703
| +3% | +$49.3K | ﹤0.01% | 3249 |
|
|
2020
Q1 | $1.45M | Sell |
53,799
-7,107
| -12% | -$212K | ﹤0.01% | 3198 |
|
|
2019
Q4 | $2.05M | Sell |
60,906
-200,753
| -77% | -$7.27M | ﹤0.01% | 3386 |
|
|
2019
Q3 | $9.8M | Buy |
261,659
+96,226
| +58% | +$3.67M | ﹤0.01% | 2166 |
|
|
2019
Q2 | $7.23M | Sell |
165,433
-835
| -0.5% | -$35.7K | ﹤0.01% | 2369 |
|
|
2019
Q1 | $7.1M | Buy |
166,268
+60,310
| +57% | +$2.7M | ﹤0.01% | 2338 |
|
|
2018
Q4 | $4.75M | Buy |
105,958
+47,002
| +80% | +$2.46M | ﹤0.01% | 2624 |
|
|
2018
Q3 | $4.04M | Buy |
58,956
+30,414
| +107% | +$1.96M | ﹤0.01% | 2936 |
|
|
2018
Q2 | $1.63M | Sell |
28,542
-171,538
| -86% | -$9.06M | ﹤0.01% | 3571 |
|
|
2018
Q1 | $9.22M | Sell |
200,080
-644,760
| -76% | -$30.6M | ﹤0.01% | 2108 |
|
|
2017
Q4 | $39M | Buy |
844,840
+39,846
| +5% | +$1.83M | 0.01% | 1126 |
|
|
2017
Q3 | $36.7M | Sell |
804,994
-73,564
| -8% | -$3.14M | 0.01% | 1105 |
|
|
2017
Q2 | $34.5M | Buy |
878,558
+169,194
| +24% | +$6.39M | 0.01% | 1113 |
|
|
2017
Q1 | $27M | Buy |
709,364
+15,142
| +2% | +$590K | 0.01% | 1277 |
|
|
2016
Q4 | $25.7M | Buy |
694,222
+85,957
| +14% | +$3.07M | 0.01% | 1307 |
|
|
2016
Q3 | $21.1M | Buy |
608,265
+532,677
| +705% | +$18.7M | 0.01% | 1337 |
|
|
2016
Q2 | $2.46M | Sell |
75,588
-2,508
| -3% | -$76.8K | ﹤0.01% | 2719 |
|
|
2016
Q1 | $2.24M | Sell |
78,096
-2,763
| -3% | -$73.6K | ﹤0.01% | 2654 |
|
|
2015
Q4 | $2.7M | Buy |
80,859
+1,012
| +1% | +$31.5K | ﹤0.01% | 2618 |
|
|
2015
Q3 | $2.27M | Sell |
79,847
-47,134
| -37% | -$1.64M | ﹤0.01% | 2693 |
|
|
2015
Q2 | $5.14M | Sell |
126,981
-211,636
| -63% | -$9.5M | ﹤0.01% | 2387 |
|
|
2015
Q1 | $16.7M | Buy |
338,617
+282,462
| +503% | +$13.1M | ﹤0.01% | 1571 |
|
|
2014
Q4 | $2.55M | Sell |
56,155
-393,724
| -88% | -$15.5M | ﹤0.01% | 2842 |
|
Other funds holding AVNS
JP Morgan Chase's AVNS Position: Q3 2026 in Review
JP Morgan Chase sold out of Avanos Medical (AVNS) in Q3 2026, closing a stake of 1,099,770 shares — an estimated $27.4M sold.
JP Morgan Chase first reported a position in AVNS in Q4 2014 and held it in 47 quarters. The position peaked at $39M in Q4 2017. 3 funds tracked by Wall St. Rank hold AVNS as of Q3 2026.
- JP Morgan Chase reported no remaining Avanos Medical position as of Q3 2026 after selling out during the quarter.
- JP Morgan Chase sold 1,099,770 Avanos Medical shares in Q3 2026, an estimated $27.4M.
- JP Morgan Chase first reported a position in Avanos Medical in Q4 2014 and held it in 47 quarters.
- JP Morgan Chase's Avanos Medical position peaked at $39M in Q4 2017.
- 3 funds tracked by Wall St. Rank held Avanos Medical as of Q3 2026.
Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.